We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Says Continuum of Biosimilarity Ratings Do Not Represent Approval Standards
FDA Says Continuum of Biosimilarity Ratings Do Not Represent Approval Standards
FDA officials sought to clear up questions about what standards the agency will apply when approving biosimilars, emphasizing that manufacturers must prove their products are “highly similar” to the reference product in order to win a green light.